EGFR, HLA-G, CD70, C-MET, and NY-ESO1 As Potential Biomarkers in High Grade Epithelial Ovarian Carcinoma

Overview

Journal Cancer Biomark

Publisher Sage Publications

Specialties Biochemistry
Oncology

Date 2024 Jan 22

PMID 38250760

Authors

Duc Vo

Yan Liu

Anil K Sood

Katy Rezvani

Amir A Jazaeri

Jinsong Liu

Affiliations

Soon will be listed here.

Abstract

High grade epithelial ovarian carcinoma is an aggressive tumor. Treatment includes platinum therapy, however it recurs in most patients due to therapy resistance. In this project, we study the immunohistochemical (IHC) expression of five potential biomarkers/prognostic markers in high grade epithelial ovarian carcinoma: EGFR, HLA-G, CD70, c-MET, and NY-ESO1. A cohort of 274 patients is used. We compare the IHC expression with age, stage, ascites status, family history of cancer, disease free survival (DFS) and overall survival (OS). EGFR expression is significantly correlated with family history and worse OS. HLA-G is associated with worse OS. To confirm the results of EGFR and HLA-G, a second separated cohort of 248 patients is used. Positive EGFR expression again shows worse OS, while HLA-G expression has worse prognostic trend. CD70 has a worse OS trend. C-MET and NY-ESO1 do not have any clinical correlations. EGFR can potentially serve as target in future clinical immune therapy trials.

References

Menier C, Prevot S, Carosella E, Rouas-Freiss N . Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol. 2009; 70(12):1006-9. DOI: 10.1016/j.humimm.2009.07.021. View

Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C . Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018; 17(1):45. PMC: 5817860. DOI: 10.1186/s12943-018-0796-y. View

Koshiyama M, Matsumura N, Konishi I . Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014; 2014:934261. PMC: 4017729. DOI: 10.1155/2014/934261. View

Mehner C, Oberg A, Goergen K, Kalli K, Maurer M, Nassar A . EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes Cancer. 2017; 8(5-6):589-599. PMC: 5511892. DOI: 10.18632/genesandcancer.142. View

Kwon Y, Godwin A . Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer. Reprod Sci. 2016; 24(4):494-501. PMC: 5933198. DOI: 10.1177/1933719116648212. View

Mallmann-Gottschalk N, Sax Y, Kimmig R, Lang S, Brandau S . EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. Int J Mol Sci. 2019; 20(19). PMC: 6801374. DOI: 10.3390/ijms20194693. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Lin A, Yan W . Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy. Mol Med. 2015; 21(1):782-791. PMC: 4749493. DOI: 10.2119/molmed.2015.00083. View

Lin C, Chao T, Yu C, Yu M, Jin J . The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 2009; 117(3):162-75. DOI: 10.1111/j.1600-0463.2008.00003.x. View

10.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H . Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11:287-299. PMC: 6500433. DOI: 10.2147/IJWH.S197604. View

11.

Shiomi M, Matsuzaki S, Serada S, Matsuo K, Mizuta-Odani C, Jitsumori M . CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer. Cancer Sci. 2021; 112(9):3655-3668. PMC: 8409415. DOI: 10.1111/cas.15027. View

12.

Terada K, Ahn H, Kessel B . Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol. 2016; 27(3):e25. PMC: 4823356. DOI: 10.3802/jgo.2016.27.e25. View

13.

Cheng W, Feng P, Lee K, Chen K, Sun W, Van Hiep N . The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci. 2021; 22(23). PMC: 8657471. DOI: 10.3390/ijms222312828. View

14.

De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F . CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck. Pathobiology. 2016; 83(6):327-33. DOI: 10.1159/000446569. View

15.

Rutten M, Dijk F, Savci-Heijink C, Buist M, Kenter G, van de Vijver M . HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J Immunol Res. 2014; 2014:274584. PMC: 4058481. DOI: 10.1155/2014/274584. View

16.

Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J . Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci. 2021; 22(12). PMC: 8234871. DOI: 10.3390/ijms22126532. View

17.

Liu N, Sheng X, Liu Y, Zhang X, Yu J . Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas. Onco Targets Ther. 2013; 6:615-9. PMC: 3681401. DOI: 10.2147/OTT.S44445. View

18.

Jung Y, Kim Y, Kim S, Kim S, Kim J, Cho N . Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer. Reprod Sci. 2009; 16(11):1103-11. DOI: 10.1177/1933719109342131. View

19.

Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl A, Sehouli J . An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer. 2011; 11:294. PMC: 3149030. DOI: 10.1186/1471-2407-11-294. View

20.

Kurman R, Shih I . The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016; 186(4):733-47. PMC: 5808151. DOI: 10.1016/j.ajpath.2015.11.011. View